PharmaCyte Biotech (OTCMKTS:PMCB) and Ocugen (NASDAQ:OCGN) Critical Review
PharmaCyte Biotech (OTCMKTS:PMCB) and Ocugen (NASDAQ:OCGN) Critical Review
Ocugen (NASDAQ:OCGN – Get Rating) and PharmaCyte Biotech (OTCMKTS:PMCB – Get Rating) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, valuation, risk, analyst recommendations, earnings, dividends and institutional ownership.
Ocugen（纳斯达克股票代码：OCGN — 获取评级）和 Pharmacyte Biotech（OTCMKTS: PMCB — 获取评级）都是小型医疗公司，但哪只是优势股？我们将根据两家公司的盈利能力、估值、风险、分析师建议、收益、股息和机构所有权进行比较。
Institutional & Insider Ownership
机构所有权和内部所有权
37.5% of Ocugen shares are held by institutional investors. Comparatively, 33.2% of PharmaCyte Biotech shares are held by institutional investors. 2.8% of Ocugen shares are held by insiders. Comparatively, 5.6% of PharmaCyte Biotech shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Ocugen的37.5％股份由机构投资者持有。相比之下，Pharmacyte Biotech的股票有33.2％由机构投资者持有。2.8％的Ocugen股票由内部人士持有。相比之下，Pharmacyte Biotech的股票中有5.6％由内部人士持有。强大的机构所有权表明大型基金经理、捐赠基金和对冲基金认为，从长远来看，一家公司的表现将优于市场。
Analyst Recommendations
分析师建议
This is a summary of current recommendations for Ocugen and PharmaCyte Biotech, as reported by MarketBeat.com.
据Marketbeat.com报道，这是目前对Ocugen和Pharmacyte Biotech的建议的摘要。
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Ocugen | 0 | 0 | 5 | 0 | 3.00 |
| PharmaCyte Biotech | 0 | 0 | 0 | 0 | N/A |
| 卖出评级 | 保持收视率 | 买入评级 | 强劲的买入评级 | 评分分数 | |
| 奥库根 | 0 | 0 | 5 | 0 | 3.00 |
| Pharmacyt | 0 | 0 | 0 | 0 | 不适用 |
Ocugen currently has a consensus price target of $4.80, suggesting a potential upside of 499.85%. Given Ocugen's higher probable upside, research analysts clearly believe Ocugen is more favorable than PharmaCyte Biotech.
Ocugen目前的共识目标价为4.80美元，表明潜在的上涨空间为499.85％。鉴于Ocugen可能有更高的上行空间，研究分析师显然认为Ocugen比Pharmacyte Biotech更有利。
Profitability
盈利能力
This table compares Ocugen and PharmaCyte Biotech's net margins, return on equity and return on assets.
该表比较了Ocugen和Pharmacyte Biotech的净利润率、股本回报率和资产回报率。
| Net Margins | Return on Equity | Return on Assets | |
| Ocugen | N/A | -76.64% | -65.51% |
| PharmaCyte Biotech | N/A | -6.71% | -6.64% |
| 净利润 | 股本回报率 | 资产回报率 | |
| 奥库根 | 不适用 | -76.64% | -65.51% |
| Pharmacyt | 不适用 | -6.71% | -6.64% |
Earnings and Valuation
收益和估值
This table compares Ocugen and PharmaCyte Biotech's top-line revenue, earnings per share and valuation.
该表比较了Ocugen和Pharmacyte Biotech的营收、每股收益和估值。
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Ocugen | $42.62 million | 4.25 | -$81.35 million | ($0.38) | -2.11 |
| PharmaCyte Biotech | N/A | N/A | -$4.24 million | ($0.26) | -11.35 |
| 总收入 | 价格/销售比率 | 净收入 | 每股收益 | 市盈率 | |
| 奥库根 | 4262 万美元 | 4.25 | -8135 万美元 | (0.38 美元) | -2.11 |
| Pharmacyt | 不适用 | 不适用 | -424 万美元 | (0.26 美元) | -11.35 |
PharmaCyte Biotech has lower revenue, but higher earnings than Ocugen. PharmaCyte Biotech is trading at a lower price-to-earnings ratio than Ocugen, indicating that it is currently the more affordable of the two stocks.
Pharmacyte Biotech的收入较低，但收益高于Ocugen。Pharmacyte Biotech的交易市盈率低于Ocugen，这表明它目前是这两只股票中更实惠的一只。
Volatility & Risk
波动性与风险
Ocugen has a beta of 3.85, suggesting that its share price is 285% more volatile than the S&P 500. Comparatively, PharmaCyte Biotech has a beta of -0.03, suggesting that its share price is 103% less volatile than the S&P 500.
Ocugen的beta值为3.85，这表明其股价的波动性比标准普尔500指数高285％。相比之下，Pharmacyte Biotech的beta值为-0.03，这表明其股价的波动性比标准普尔500指数低103％。
Summary
摘要
Ocugen beats PharmaCyte Biotech on 6 of the 11 factors compared between the two stocks.
在两只股票比较的11个因素中，Ocugen在6个因素上击败了PharmacYte Biotech。
About Ocugen
关于 Ocugen
(Get Rating)
（获取评分）
Ocugen, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies to cure eye diseases. Its product pipeline candidates include OCU400, OCU410, OCU200, and COVAXIN. The firm's modifier gene therapy platform is engaged in addressing retinal diseases, including retinitis pigmentosa, leber congenital amaurosis, and dry age-related macular degeneration. The company was founded by Shankar Musunuri and Uday B. Kompella in 2013 and is headquartered in Malvern, PA.
Ocugen, Inc. 是一家生物制药公司，从事治疗眼部疾病的疗法的开发和商业化。其候选产品线包括 OCU400、OCU410、OCU200 和 COVAXIN。该公司的修正基因疗法平台致力于治疗视网膜疾病，包括色素性视网膜炎、莱伯先天性黑蒙病和与年龄相关的干性黄斑变性。该公司由 Shankar Musunuri 和 Uday B. Kompella 于 2013 年创立，总部位于宾夕法尼亚州马尔文。
About PharmaCyte Biotech
关于 Pharmacyte
(Get Rating)
（获取评分）
PharmaCyte Biotech, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of treatments for cancer and diabetes. It focuses on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box, which will be used as a platform for the development of treatments for inoperable pancreatic cancer and other solid cancerous tumors, and diabetes. The company was founded on October 28, 1996 and is headquartered in Las Vegas, NV.
Pharmacyte Biotech, Inc. 是一家临床阶段的生物技术公司，从事癌症和糖尿病治疗的开发和商业化。它专注于一种名为Cell-in-a-Box的基于纤维素的专有活细胞封装技术，该技术将用作开发无法手术的胰腺癌和其他实体癌肿瘤以及糖尿病治疗的平台。该公司成立于1996年10月28日，总部位于内华达州拉斯维加斯。
Receive News & Ratings for Ocugen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ocugen and related companies with MarketBeat.com's FREE daily email newsletter.
接收 Ocugen Daily 的新闻和收视率 -在下面输入您的电子邮件地址，以通过Marketbeat.com的免费每日电子邮件时事通讯接收Ocugen及相关公司最新新闻和分析师评级的简明每日摘要。